Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer

Bingshu Xia; Ming Shan; Ji Wang; Zhenbin Zhong; Jingshu Geng; Xiaohui He; Tung Vu; Dekai Zhang; Da Pang

doi:10.18632/oncotarget.14216

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer

Bingshu Xia _, Ming Shan, Ji Wang, Zhenbin Zhong, Jingshu Geng, Xiaohui He, Tung Vu, Dekai Zhang and Da Pang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:9794-9805. https://doi.org/10.18632/oncotarget.14216

Metrics: PDF 1539 views | HTML 1837 views | ?

Abstract

Bingshu Xia1, Ming Shan1, Ji Wang1, Zhenbin Zhong1, Jingshu Geng2, Xiaohui He3, Tung Vu4, Dekai Zhang4, Da Pang1,5

1Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, China

2Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 150081, China

3Department of Medical Records, Harbin Medical University Cancer Hospital, Harbin, 150081, China

4Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas, 77030, USA

5Heilongjiang Academy of Medical Sciences, Heilongjiang Province, Harbin, 150086, China

Correspondence to:

Da Pang, email: [email protected]

Dekai Zhang, email: [email protected]

Keywords: breast cancer, DNA methylation, HOX genes, biomarker, prognosis

Received: April 12, 2016 Accepted: December 05, 2016 Published: December 25, 2016

ABSTRACT

Homeobox A11 (HOXA11) is one of the hypermethylated genes in breast cancer and its function in breast tumorigenesis remains elusive. In this study, we analyzed the methylation status of HOXA11 in 264 paired breast cancer and normal tissue as well as in matched serum samples by MethyLight assay. Further, the function of HOXA11 in breast tumorigenesis was analyzed by cell proliferation and migration assays. We found that HOXA11 was hypermethylated in cancer tissues (45.08%), especially in invasive ductal carcinomas (P<0.001), patients with a family history of cancer (P=0.033), cases with metastatic lymph nodes (P=0.004) and P53 positive group (P=0.017). Kaplan-Meier survival analysis and Cox regression analysis revealed that HOXA11 hypermethylation is an independent predictor of poor outcomes. The over expression of HOXA11 suppressed cell growth in MDA-MB-231, MCF7, SKBR3 and BT474 cells. In conclusion, the hypermethylation of HOXA11 is an independent prognostic biomarker in breast cancer. Additionally, HOXA11 can be a potential tumor suppressor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14216

Publication Alerts

Research Papers:

Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer

Abstract